- Home
- ALT vs SOPH Comparison
ALT vs SOPH Comparison
Compare ALT & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | SOPH |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.5M | 462.3M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALT | SOPH |
|---|---|---|
| Price | $2.99 | $5.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $17.67 | $7.50 |
| AVG Volume (30 Days) | ★ 3.3M | 353.9K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | $23.09 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.56 | $2.92 |
| 52 Week High | $6.44 | $6.77 |
Technical Indicators
Market Signals| Indicator | ALT | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 46.49 |
| Support Level | $2.87 | $4.63 |
| Resistance Level | $3.09 | $6.30 |
| Average True Range (ATR) | 0.16 | 0.37 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 41.07 | 10.33 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.